By Marco Rauland, Ph.D., Head of Pricing & Market Access

In the June issue of Pipeline, we discussed the direct price questioning techniques using predefined price points. This article will deal with direct price questioning methodologies without any aid on price points. 

The Price Sensitivity Meter (PSM) was introduced in 1976 by the Dutch economist Peter van Westendorp and has been used by a wide variety of researchers in the market research industry. The Van Westendorp/PSM technique is based on four questions.

By Chris Krattiger, Head of Global Marketing, GfK HealthCare

What are biosimilars?

Although generics – which are copies of chemically produced drugs – have been around for decades, biosimilars are so-called ‘new land.’ 

Much has been said about biosimilars, but many uncertainties still exist around this new generation of drugs.

The term biosimilars is derived from “similar biological medicinal products,” and biosimilars can be produced and marketed after patent expiry of an original biologic. Laymen often refer to these products as generic biologics – as they intend to be copies of the original brand – but as the name biosimilar already reveals, they are similar rather than the same.

Data Download provides highlights of recently released data from GfK HealthCare. This month's selection covers research from studies conducted in the area of oncology.

We invite you to join GfK HealthCare Sept. 27-29 in Shanghai at the European Pharmaceutical Marketing Research Association’s (EphMRA) 2011 Asia Conference. In keeping with the conference theme, Asia in the Spotlight, GfK HealthCare will give a presentation highlighting unique challenges and solutions for making better forecasts in the Asian market.

Click here to read the issue, which includes:

- Measuring Customer Loyalty: Integrating Feedback Into the Rep Compensation Plan
- ASCO Annual Meeting Buzz: Advancements in Treating Smaller Oncology Indications

Pipeline archive is available. Skim the directory and select articles you missed. Access subscriber opt-in/comment form.